| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr182.25 |
| 52 Week High | kr241.20 |
| 52 Week Low | kr169.00 |
| Beta | 1.58 |
| 1 Month Change | -7.16% |
| 3 Month Change | 8.42% |
| 1 Year Change | -20.69% |
| 3 Year Change | -34.32% |
| 5 Year Change | -8.32% |
| Change since IPO | 33.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| VITRS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.1% |
| 1Y | -20.7% | -25.7% | 1.9% |
Return vs Industry: VITRS exceeded the UK Biotechs industry which returned -25.7% over the past year.
Return vs Market: VITRS underperformed the UK Market which returned 1.9% over the past year.
Price Volatility
| VITRS volatility | |
|---|---|
| VITRS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VITRS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VITRS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,132 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products. It also offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. In addition, the company offers EmbryoScope and time-lapse systems; time-lapse dishes; and evaluation tools for time-lapse systems.
Vitrolife AB (publ) Fundamentals Summary
| VITRS fundamental statistics | |
|---|---|
| Market cap | kr22.52b |
| Earnings (TTM) | -kr3.84b |
| Revenue (TTM) | kr3.50b |
6.4x
P/S Ratio-5.9x
P/E RatioIs VITRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VITRS income statement (TTM) | |
|---|---|
| Revenue | kr3.50b |
| Cost of Revenue | kr1.53b |
| Gross Profit | kr1.97b |
| Other Expenses | kr5.81b |
| Earnings | -kr3.84b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | -28.33 |
| Gross Margin | 56.39% |
| Net Profit Margin | -109.63% |
| Debt/Equity Ratio | 14.9% |
How did VITRS perform over the long term?
See historical performance and comparison